CON — Concentra Group Holdings Parent, Inc. stock price, charts and financials
QT76Concentra Group Holdings Parent, Inc.Concentra Group Holdings Parent, Inc. (NYSE: CON) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 23.03 | EPS (ttm) | 1.54 | Insider Own | 6.16% | Shs Outstand | 127.96M | Perf Week | 1.49% |
| Market Cap | 4.54B | Forward P/E | 19.29 | EPS next Y | 1.84 | Insider Trans | -6.60% | Shs Float | 114.50M | Perf Month | 2.01% |
| Enterprise Value | 6.44B | PEG | 2.27 | EPS next Q | 0.44 | Inst Own | - | Short Float | 2.45% | Perf Quarter | 24.19% |
| Income | 198.00M | P/S | 1.98 | EPS this Y | 7.07% | Inst Trans | - | Short Ratio | 2.94 | Perf Half Y | 61.89% |
| Sales | 2.29B | P/B | 8.97 | EPS next Y | 11.52% | ROA | 6.60% | Short Interest | 2.80M | Perf YTD | 80.23% |
| Book/sh | 3.95 | P/C | 28.73 | EPS next 5Y | 10.14% | ROE | 47.30% | 52W High | 36.71 -3.38% | Perf Year | 70.69% |
| Cash/sh | 1.23 | P/FCF | 12.79 | EPS past 3/5Y | -0.51% - | ROIC | 10.51% | 52W Low | 18.55 91.21% | Perf 3Y | - |
| Dividend Est. | 0.25 (0.70%) | EV/EBITDA | 13.96 | Sales past 3/5Y | 7.85% - | Gross Margin | 29.31% | Volatility | 3.18% 2.33% | Perf 5Y | - |
| Dividend TTM | 0.25 (0.70%) | EV/Sales | 2.81 | EPS Y/Y TTM | 18.46% | Oper. Margin | 16.39% | ATR (14) | 0.94 | Perf 10Y | - |
| Dividend Ex-Date | Aug 20, 2026 | Quick Ratio | 1.38 | Sales Y/Y TTM | 20.42% | Profit Margin | 8.69% | RSI (14) | 59.11 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.38 | EPS Q/Q | 40.54% | SMA20 | 2.02% | Beta | 0.41 | Target Price | 38.60 |
| Payout | 0.01% | Debt/Eq | 4.80 | Sales Q/Q | 9.98% | SMA50 | 6.16% | Rel Volume | 4.94 | Prev Close | 35.53 |
| Employees | 9,983 | LT Debt/Eq | 4.78 | Earnings | Nov 05 | SMA200 | 37.15% | Avg Volume | 983.46K | Price | 35.47 |
| IPO Date | Jul 25, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 23.33% 2.41% | Net Debt/EBITDA | 4.32 | Volume | 4,855,019 | Change | -0.17% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-11-26 | Reiterated | Wells Fargo | Overweight | $40 |
| Aug-10-26 | Reiterated | Deutsche Bank | $32 → $41 | |
| Aug-10-26 | Reiterated | Mizuho Securities | $35 → $40 | |
| Aug-10-26 | Reiterated | Truist Securities | Buy | $37 → $42 |
| Jul-14-26 | Reiterated | Truist Securities | Buy | $29 → $37 |
| Jun-05-26 | Reiterated | Goldman Sachs | Buy | $26 → $30 |
| May-08-26 | Reiterated | Deutsche Bank | $29 → $32 | |
| Feb-02-26 | Reiterated | RBC Capital | Outperform | $31 |
| Oct-14-25 | Reiterated | UBS | $38 → $52 | |
| Mar-06-25 | Reiterated | Goldman Sachs | $24 → $26 |
Concentra Group Holdings Parent, Inc. is a U.S.-based provider of occupational health solutions. The company delivers a comprehensive suite of occupational and consumer health services, encompassing treatment for workers' compensation injuries, urgent care, diagnostic clinical testing, preventative health measures, and employer-specific programs, along with wellness initiatives. These services are accessible through their network of occupational health centers and onsite clinics. Furthermore, Concentra offers specialized solutions like Concentra Telemed, a telemedicine platform for addressing work-related injuries and illnesses and supporting employer services; Concentra Pharmacy, providing pharmaceutical solutions; and Concentra Medical Compliance Administration, a third-party administrative service that assists employers in managing drug abuse testing programs for both regulated and non-regulated workforces. Established in 1979 and headquartered in Mechanicsburg, Pennsylvania, the company functions as a subsidiary of Select Medical Corporation.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 2,288 | 2,163 | 1,900 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,617 | 1,550 | 1,372 | — | — | — | |
| Gross Profit | 670 | 613 | 528 | — | — | — | |
| Selling, General and Administrative Excl. Other | 216 | 203 | 156 | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | |
| Other Operating Expense | 80 | 76 | 67 | — | — | — | |
| Operating Income | 375 | 334 | 305 | — | — | — | |
| Interest Expense | 108 | 109 | 70 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | -1 | -4 | — | — | — | |
| Net Income Before Taxes | 268 | 224 | 231 | — | — | — | |
| Income Taxes | 62 | 51 | 59 | — | — | — | |
| Consolidated Net Income | 198 | 166 | 167 | — | — | — | |
| Net Income From Continuing Operations | 205 | 173 | 172 | — | — | — | |
| Net Income | 198 | 166 | 167 | — | — | — | |
| EPS (Recurring) | 1.55 | 1.39 | 1.30 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.55 | 1.39 | 1.30 | — | — | — | |
| EPS (Diluted) | 1.54 | 1.30 | 1.30 | — | — | — | |
| EBITDA | 461 | 409 | 368 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | 23.03 | 15.14 | 15.22 | — | — | — | |
| Price To Sales Ratio | 1.97 | 1.16 | 1.33 | — | — | — | |
| Gross Margin | 29.28 | 28.34 | 27.79 | — | — | — | |
| Operating Margin | 16.39 | 15.44 | 16.05 | — | — | — | |
| Net Margin | 8.65 | 7.67 | 8.79 | — | — | — | |
| Shares Outstanding | 127 | 127 | 128 | — | — | — | |
| Market Capitalization | 4,505 | 2,499 | 2,532 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ORTENZIO ROBERT A | Director | Aug 03 '26 | Sale | 31.84 | 130,000 | 4,139,356 | 503,455 | Aug 05 |
| ORTENZIO ROBERT A | Director | Jul 01 '26 | Sale | 30.50 | 130,000 | 3,964,597 | 633,455 | Jul 06 |
| ORTENZIO ROBERT A | Director | Jun 01 '26 | Sale | 25.00 | 130,000 | 3,250,026 | 763,455 | Jun 02 |
| ORTENZIO ROBERT A | Director | May 08 '26 | Sale | 25.00 | 130,000 | 3,250,000 | 893,455 | May 11 |